Correlate Biomarkers for the SYNERGY- 201 Study
Status
RECRUITING
Phase
Age
≥ 18 Years
Enrollments
48Conditions
Prostate CancerSummary
This study is a companion to the SYNERGY-201 clinical trial (NCT06228053), which investigates SX-682 and enzalutamide in individuals with prostate cancer. Individuals must be participating in SYNERGY-201 in order to participate in this study. The purpose of this companion study is to learn more about biomarkers, particularly a biomarker called CXCR2, and investigate if CXCR2 can predict who will receive benefit from the SYNERGY-201 drug combination. This study will also investigate how CXCR2 and other biomarkers change over time when participants receive the SYNERGY-201 drug combination. CXCR2 is of particular interest because the SYNERGY-201 drug, SX-682, inhibits CXCR2. After participants provide consent, blood samples will be collected for research purposes at three SYNERGY-201 visits (Baseline, Cycle 3 Day 1 and End of Study Drug). Up to 20 participants will also receive tumor biopsies at the Baseline and SYNERGY-201 Cycle 3 Day 1 visits. Clinical and study data collected as part of SYNERGY-201 will also be used for this study.
Locations
1 location Found with status Recruiting
Status
- RECRUITING
Contact Person
- Monika Monika Anand, PhD
- 919-681-8838
- [email protected]
Principal Investigator
- Andrew Armstrong, MD
Eligibility Criteria
Inclusion Criteria:
* Willing and able to provide written informed consent for this study and HIPAA authorization for the release of personal health information.
* Age >18
* Participating in the SYNGERY-201 clinical trial.
Exclusion Criteria:
* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study
* History or current evidence of any condition, therapy, or laboratory abnormality that might interfere with the subject's participation for the full duration of the study
* History or current evidence of any condition, therapy, or laboratory abnormality that is not in the best interest of the subject to participate (in the opinion of the treating investigator)
Study Plan
Men who are participating in the SYNERGY-201 clinical trial (NCT06228053).
Men with metastatic castration resistant prostate cancer (mCRPC) who are participating in the SYNERGY-201 clinical trial (NCT06228053) and who also agree to participate in this study will have blood collected for circulating tumor DNA (ctDNA) and immune cell profiling assessments and other research assessments at baseline, Cycle 3 Day 1 of SYNERGY-201 and at the time of the decision to discontinue the SYNERGY-201 study drug. A subset of up to 20 participants will also undergo tumor biopsies at the baseline and Cycle 3 Day 1 visits of SYNERGY-201.
DIAGNOSTIC_TEST:
CXCR2 as a biomarkerDescription:
CXCR2 biomarker expression will be measured in tumor and immune cell samples
Outcome Measures
Primary Outcome Measures
Number of participants with Tumor CXCR2 biomarker expression associated with clinical benefit (CB)
Number of participants with Immune cell CXCR2 biomarker expression associated with clinical benefit (CB)
Timeline
Last Updated
August 11, 2025Start Date
July 3, 2025Today
October 17, 2025Completion Date ( Estimated )
October 1, 2026
Sponsors of this trial
Lead Sponsor
Duke UniversityCollaborating Sponsors
Prostate Cancer Foundation
RECRUITING 
≥ 18 Years